Repare Therapeutics
Logotype for Repare Therapeutics Inc

Repare Therapeutics (RPTX) investor relations material

Repare Therapeutics has been acquired

Repare Therapeutics Proxy Filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Repare Therapeutics Inc
Proxy Filing summary29 Dec, 2025

Executive summary

  • Gilead Sciences agreed to acquire all assets related to the RP-3467 program, a clinical-stage polymerase theta ATPase inhibitor, from the seller for up to $30 million, including $22 million upfront, a $3 million holdback, and a $5 million transfer completion payment.

  • The transaction excludes other programs, employee contracts, cash, accounts receivable, real property, and equipment, focusing solely on the RP-3467 program and associated assets.

  • The board of directors approved the asset sale, which is expected to increase the estimated cash payment to shareholders in a pending acquisition by Xeno Therapeutics.

  • The asset purchase agreement includes customary representations, warranties, covenants, and indemnification provisions, with specific limitations on liability and recovery.

  • The transaction is not considered a merger or continuation of the seller’s business, and Gilead assumes only certain post-closing liabilities.

Voting matters and shareholder proposals

  • A special meeting of shareholders is scheduled for January 16, 2026, to approve the acquisition of all outstanding shares by Xeno Therapeutics.

  • Shareholders will vote on the proposed transaction with Xeno, with the proxy statement providing details on the arrangement and estimated per-share cash payment.

Board of directors and corporate governance

  • The board of directors approved the asset sale to Gilead and the arrangement agreement with Xeno Therapeutics.

  • Directors, executive officers, and employees may be considered participants in the proxy solicitation for the Xeno transaction.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
Repare Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Repare Therapeutics Inc. (RPTX) is a clinical-stage precision oncology company focused on the development of novel therapeutics using its synthetic lethality approach. The company leverages its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies aimed at genomic instability, including DNA damage repair.